Fingolimod Associated Bilateral Cystoid Macular Edema—Wait and See?
AbstractFingolimod 0.5-mg once-daily is an approved therapy for patients with relapsing–remitting multiple sclerosis (MS). Several pivotal and real-world studies have demonstrated that fingolimod is associated with the development of macular edema (ME). Herein, we present a case of a diabetic MS patient who developed severe bilateral ME during fingolimod treatment. By means of this case study we provide a detailed review about fingolimod associated macular edema (FAME), its current incidence with or without diabetes mellitus, and previous therapy attempts and outcomes in MS patients. Intravitreal administration of antibodies raised against vascular endothelial growth factor A (VEGF-A) has not yet been used in the management of FAME, however, the excellent therapeutic response in our patient may justify the use of anti-VEGF-A agents in combination with cessation of fingolimod to achieve fast resolution of FAME and to prevent visual deficits, particularly in bilateral FAME. View Full-Text
Share & Cite This Article
Pul, R.; Osmanovic, A.; Schmalstieg, H.; Pielen, A.; Pars, K.; Schwenkenbecher, P.; Sühs, K.W.; Yildiz, Ö.; Frank, B.; Stangel, M.; Skripuletz, T. Fingolimod Associated Bilateral Cystoid Macular Edema—Wait and See? Int. J. Mol. Sci. 2016, 17, 2106.
Pul R, Osmanovic A, Schmalstieg H, Pielen A, Pars K, Schwenkenbecher P, Sühs KW, Yildiz Ö, Frank B, Stangel M, Skripuletz T. Fingolimod Associated Bilateral Cystoid Macular Edema—Wait and See? International Journal of Molecular Sciences. 2016; 17(12):2106.Chicago/Turabian Style
Pul, Refik; Osmanovic, Alma; Schmalstieg, Holger; Pielen, Amelie; Pars, Kaweh; Schwenkenbecher, Philipp; Sühs, Kurt W.; Yildiz, Özlem; Frank, Benedikt; Stangel, Martin; Skripuletz, Thomas. 2016. "Fingolimod Associated Bilateral Cystoid Macular Edema—Wait and See?" Int. J. Mol. Sci. 17, no. 12: 2106.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.